前列腺癌患者^89Sr核素治疗后免疫功能的变化

目的：探讨分析前列腺癌患者^89Sr治疗后机体免疫功能的变化及其临床意义。方法：87例前列腺癌患者经^89Srcl2治疗1月，采用流式细胞术检测治疗前后其外周血淋巴细胞亚群，速率散射免疫比浊分析法检测其免疫球蛋白的含量。结果：经^89Sr治疗后，患者CD3、CD19、CD4比例均明显升高，CD8比例明显降低，差异均有统计学意义畔0．05），而CD16^＋CD56^＋无明显变化；IgG和IgA明显升高，差异均有统计学意义（P〈0．05），而IgM无明显变化。结论：用^89Srcl2治疗前列腺癌可以有效提高患者的免疫水平，可通过监测机体免疫功能指标的变化^89Sr核素的疗效。

Change of Immune Function in Prostate Cancer after Treated with ^89Sr and its Clinical Significance

Objective： To explore the change of immune function in prostate cancer patients after treated with ^89Sr and its clinical significance. Methods： The peripheral blood lymphocyte subsets were detected by flow cytometry after 87 cases of prostate cancer patients were treated with ^89Sr for one month, and immunoglobulin levels were detected by rate scattering immunoturbidimetric assay. Results： After treatment with ^89Sr, the ratio of CD3, CD 19 and CD4 were significantly higher than before treatment, and the ratio of CD8 was significantly lower than before treatment（P〈0.05）, but there was no significant difference of CD16^＋CD56^＋. The levels oflgG and IgA were both significantly higher than before treatment（P〈0.05）, but there was no significant difference of IgM. Conclusions： Treatment with ^89Sr-chloride was effective for prostate cancer which was able to improve the immune function, change of immune function may be used to evaluate the clinical efficay of ^89Sr.